TrialCancer2020

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.

Darren R Feldman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.